Reis, BY
[34]USAOct 2021BNT162b2 (Pfizer-BioNTech)Retrospective case control12 to 18184,905June 2021–Sept 2021 (Delta)93 (88 to 97) against symptomatic
infection, days 7 to 21 after second dose 90 (88 to 92) against documented infection, days 7 to 21 after second doseOlson, SM [35]USAOct 2021BNT162b2 (Pfizer-BioNTech)Case-control study12 to 18572June 2021–Sept 2021 (Delta) 93 (83 to 97)No vaccinated
adolescents were
admitted to the ICUGlatman-Freedman, A [36]IsraelNov 2021BNT162b2 (Pfizer-BioNTech)Retrospective cohort study12 to 15All 12–15 years old in Israel excluding
those with positive
COVID-19 PCR July 2021–Aug 2021 (Delta)88.2 (85.0 to 90.7)No vaccinated adolescents who became SARS-CoV-2-positive were hospitalized 1–28 days
after primary vaccine series Choe, YJ
[17]South KoreaDec 2021BNT162b2 (Pfizer-BioNTech)Retrospective cohort study16 to 181,299,965July 2021–Nov 2021 (Delta)Against asymptomatic or symptomatic COVID infection: 99.1 (98.5 to 99.5)Lutrick, K [37]USADec 2021BNT162b2 (Pfizer-BioNTech)Prospective cohort study12 to 17243July 2021–Dec 2021 (Delta)94 (83 to 98) Zambrano, LD [18]USAJan 2022BNT162b2 (Pfizer-BioNTech)Retrospective case control12 to 18117July 2021–Dec 2021 (Delta) 91 (78 to 97) against MIS-CNo vaccinated
adolescent with MIS-C
required life supportOne patient (20%)
required ICU admissionLin, DY [38]USAJan 2022BNT162b2 (Pfizer-BioNTech)Retrospective review study12–17 (stratified)806,634Dec 2020–Sept 2021 (Delta)95.2 (94.5 to 95.7)
one month after first dose Olson, SM
[35]USAFeb 2022BNT162b2 (Pfizer-BioNTech)Retrospective case control12 to 181222July 2021–Oct 2021 (Delta) 94 (90 to 96)98 (93 to 99)Oliveira, CR [39]USAMarch 2022BNT162b2 (Pfizer-BioNTech)Retrospective case control12 to 18542June 2021–Aug 2021 (Delta)91 (80 to 96) symptomatic
93 (81 to 97) asymptomatic
94 (75 to 98) during Delta Klein, NP [40]USAMarch 2022BNT162b2 (Pfizer-BioNTech)Retrospective review study5 to 1740,916 urgent care, emergency
department, or hospitalization
encountersApr 2021–Jan 202246 (24 to 61) in 5–11 year-olds;
51 (30 to 65) during Omicron74 (−35 to 95) in 5–11 year-olds during Delta or Omicron (Delta/Omicron)83 (80 to 85) in 12–15 year-olds;
92 (89 to 94) during Delta;
45 (30 to 57) during Omicron92 (79 to 97) in 12–15 year-olds during Delta or Omicron 76 (71 to 80) in 16–17 year-olds;
85 (81 to 89) during Delta;
34 (8 to 53) during Omicron94 (87 to 97) in 16–17 year-olds during Delta or OmicronPrice, AM [41]USAMarch 2022BNT162b2 (Pfizer-BioNTech)Case-control study5 to 182812July 2021–Feb 2022 (Delta/Omicron)91 (86 to 94) in 12–18 year-olds
during Delta92 (89 to 95) in 12–18 year-olds during Delta96 (90 to 98)
in 12–18 year-olds
during Delta20 (−25 to 49) in 12–18 year-olds
during Omicron40 (9 to 60) in 12–18 year-olds during Omicron79 (51 to 91)
in 12–18 year-olds
during Omicron 68 (42 to 82) in 5–11 year-olds during Omicron Fowlkes, AL [42]USAMarch 2022BNT162b2 (Pfizer-BioNTech)Prospective
cohort study5 to 151364July 2021–Feb 2022 (Delta/Omicron)Against asymptomatic or symptomatic COVID: 47 (32 to 59) in 5–11 year-olds
during Omicron93 (76 to 98) in 12–15 year olds
during Delta62 (30 to 79) in 12–15 year olds
during OmicronLi, M [16]ChinaApril 2022“China-made COVID-19 vaccines”
(inactivated, adenovirus-vectored,
recombinant-subunit
vaccine)Retrospective, descriptive analysis3 to 17 (stratified)1196May 2021–Feb 2022
(Delta/Omicron) Odds Ratio of
COVID pneumonia:
0.42 (0.31–0.57)
during Delta1.44 (0.32–6.37)
during OmicronCohen-Stavi, CJ [43]IsraelJuly 2022BNT162b2 (Pfizer-BioNTech)Observational cohort study5 to 11556,808Nov 2021–Jan 2022 (Omicron)Against documented infection:
51 (39 to 61) 68 (43 to 84) in 5–6 year-olds56 (41 to 68) in 7–9 year-olds38 (18 to 53) in 10–11 year-oldsAgainst symptomatic infection:
48 (29 to 63)69 (30 to 91) in 5–6 year-olds49 (6 to 76) in 7–9 year-olds36 (0 to 61) in 10–11 year-oldsAt 7 to 21 days after primary vaccine series